Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 7/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | EDNRA | P25101 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2882638 | 1.00 | OPRL1 (0.33) | OPRL1KCNH2CYP3A4CYP2C19EDNRA | |
| SCHEMBL2882647 | 1.00 | OPRL1 (0.33) | OPRL1KCNH2CYP3A4CYP2C19EDNRA | |
| SCHEMBL12975913 | 0.92 | ALDH1A1 (0.31) | OPRL1CYP3A4CYP2C19ALDH1A1L3MBTL1 | |
| SCHEMBL12975879 | 0.83 | OPRL1 (0.37) | OPRL1KCNH2 | |
| SCHEMBL2883261 | 0.80 | OPRL1 (0.39) | OPRL1KCNH2 | |
| SCHEMBL2877878 | 0.80 | OPRL1 (0.39) | OPRL1KCNH2 | |
| SCHEMBL2881937 | 0.79 | KMT2A (0.32) | OPRL1EDNRAALDH1A1L3MBTL1 | |
| SCHEMBL2881932 | 0.79 | KMT2A (0.32) | OPRL1EDNRAALDH1A1L3MBTL1 | |
| SCHEMBL2881576 | 0.78 | OPRL1 (0.36) | OPRL1KCNH2EDNRAALDH1A1 | |
| SCHEMBL2877829 | 0.78 | ALDH1A1 (0.30) | CYP3A4CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7855294-B2 | Cycloalkanopyridine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-12-21 | — | — | US | disclosed |
| US-20070191419-A1 | Cycloalkanopyridine derivative | MSD K.K. (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1726590-A1 | CYCLOALKANOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191419-A1 | Cycloalkanopyridine derivative | OPRL1, OPRK1, AVPR2 | OPRL1 1/4885KCNH2 969/4885CYP3A4 4560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.